Medicus Pharma Ltd. (MDCX)
NASDAQ: MDCX · Real-Time Price · USD
2.050
+0.130 (6.77%)
At close: Dec 5, 2025, 4:00 PM EST
2.099
+0.049 (2.39%)
After-hours: Dec 5, 2025, 7:41 PM EST
Company Description
Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States.
It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin.
Medicus Pharma Ltd. has a strategic collaboration with the Gorlin Syndrome Alliance to access to SKINJECT in Patients with Gorlin Syndrome.
The company was formerly known as Interactive Capital Partners Corporation and changed its name to Medicus Pharma Ltd. in September 2023.
The company was incorporated in 2008 and is headquartered in Conshohocken, Pennsylvania.
Medicus Pharma Ltd.
| Country | United States |
| Founded | 2008 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| CEO | Raza Bokhari |
Contact Details
Address: 300 Conshohocken State Road, Suite 200 Conshohocken, Pennsylvania 19428 United States | |
| Phone | 610 540 7515 |
| Website | medicuspharma.com |
Stock Details
| Ticker Symbol | MDCX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001997296 |
| ISIN Number | CA58471K2020 |
| Employer ID | 98-1778211 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Raza Bokhari M.B.A., M.D., MBA | Chief Executive Officer and Executive Chairman |
| James P. Quinlan CPA | Chief Financial Officer (Leave of Absence) |
| Dr. Edward J. Brennan Jr., F.A.C.S., FACS, M.D. | Chief Scientific Officer and Head of Research & Development Program |
| Andrew Alasdair Smith | Chief Operating Officer |
| Anna Baran-Djokovic J.D. | Senior Vice President of Investor Relations |
| Viktoria Slepeniuk | Senior Vice President of Public Relations |
| Dr. Faisal Mehmud M.D. | Chief Medical Officer |
| Maryann Adesso | Chief of Staff and Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 5, 2025 | 424B3 | Prospectus |
| Dec 4, 2025 | EFFECT | Notice of Effectiveness |
| Dec 1, 2025 | 253G2 | Acc-no: 0001493152-21-027927 (33 Act) |
| Dec 1, 2025 | 424B3 | Prospectus |
| Dec 1, 2025 | 424B3 | Prospectus |
| Dec 1, 2025 | 424B3 | Prospectus |
| Dec 1, 2025 | 424B3 | Prospectus |
| Dec 1, 2025 | 424B3 | Prospectus |
| Dec 1, 2025 | 8-K | Current Report |
| Nov 19, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |